Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $49 to $50.
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $49 to $50.